Therapeutics

Tools

Back to the Top
Search By Attributes

Search Results

Name Synonyms FDA Status Company Target Type Therapy Type Approved
For
AADvac1 Axon peptide 108 conjugated to KLH Alzheimer's Disease (Phase 2), Progressive Nonfluent Aphasia (Phase 1) Axon Neuroscience SE Tau Immunotherapy (active)
ABvac 40 Alzheimer's Disease (Phase 2) Araclon Biotech Amyloid-Related Immunotherapy (active)
ACI-24 Pal1-15 acetate salt Alzheimer's Disease (Phase 1/2), Down's Syndrome (Phase 1) AC Immune SA Amyloid-Related Immunotherapy (active)
ACI-35 Alzheimer's Disease (Phase 1) AC Immune SA, Janssen Tau Immunotherapy (active)
AL002 Alzheimer's Disease (Phase 1) AbbVie, Alector Inflammation Immunotherapy (active)
AL003 Alzheimer's Disease (Phase 1) AbbVie, Alector Inflammation Immunotherapy (active)
AN-1792 AIP 001 Alzheimer's Disease (Discontinued) Janssen, Pfizer Amyloid-Related Immunotherapy (active) None
Affitope AD02 Alzheimer's Disease (Phase 2) AFFiRiS AG Amyloid-Related Immunotherapy (active)
CAD106 Alzheimer's Disease (Phase 2/3) Novartis Pharmaceuticals Corporation Amyloid-Related Immunotherapy (active) None
Lu AF20513 Alzheimer's Disease (Phase 1) H. Lundbeck, Otsuka Pharmaceutical Co., Ltd. Amyloid-Related Immunotherapy (active)
UB 311 Alzheimer's Disease (Phase 2) United Neuroscience Amyloid-Related Immunotherapy (active)
Vanutide cridificar ACC-001,
PF-05236806
Alzheimer's Disease (Discontinued) Janssen Amyloid-Related Immunotherapy (active) None